バイオシミュレーションの世界市場レポート 2025年

バイオシミュレーションの市場規模は、今後数年で急成長が見込まれます。2029年には複合年間成長率（CAGR）17.8％で96億5,000万米ドルに成長します。予測期間の成長は、希少疾患研究におけるバイオシミュレーション、薬力学モデリングへの注力、臨床試験における患者層別化、バイオ医薬品の急成長、薬剤再利用のバイオシミュレーション、より安全で効能の高い薬剤の需要などに起因しています。予測期間における主な動向としては、デジタル研究開発戦略、シミュレーションソフトウェアの技術的進歩、バイオマーカー同定のバイオシミュレーション、臨床試験デザインの最適化、デジタルバイオマーカーとエンドポイント、計算生物学の継続的進歩などが挙げられます。

世界のヘルスケア支出の増加は、予測期間中のバイオシミュレーション市場を強化すると予想されます。ヘルスケア支出の増加は、医薬品開発への投資の増加につながり、バイオシミュレーションソリューションからの収益を押し上げると予想されます。バイオシミュレーションソフトウェアは、疾病をシミュレーションするために医薬品開発でますます活用されるようになっています。この技術は、コンピュータを使って病気のシミュレーションを行うことで、新薬のバーチャル臨床試験を可能にします。例えば、2024年7月、米国を拠点とする団体である米国医師会は、2022年の米国のヘルスケア支出が4.1％増加し、4兆5,000億米ドル（1人当たり1万3,493米ドル）に達したと報告しました。したがって、ヘルスケア支出の急増がバイオシミュレーション市場の成長を牽引しています。

慢性疾患の有病率の上昇は、バイオシミュレーション市場の今後の成長を促進すると予想されます。慢性疾患は、長期間、多くの場合、人の生涯にわたって持続する病状です。バイオシミュレーションは、慢性疾患の根底にある複雑なメカニズムを理解し、医薬品開発や個別化治療戦略を支援する上で重要な役割を果たしています。例えば、スイスに本部を置く国連の専門機関である世界保健機関（WHO）によると、2023年9月現在、世界における非感染性疾患（NCDs）または慢性疾患に起因する死亡者数は4,100万人で、全体の74％を占めています。これらの死亡者数は、心血管疾患による死亡が1,790万人、がんによる死亡が930万人、慢性呼吸器疾患による死亡が410万人、糖尿病による死亡が200万人です。したがって、慢性疾患の有病率の上昇がバイオシミュレーション市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のバイオシミュレーション市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオシミュレーション市場の成長率分析
• 世界のバイオシミュレーション市場の実績：規模と成長、2019～2024年
• 世界のバイオシミュレーション市場の予測：規模と成長、2024～2029年、2034年
• 世界のバイオシミュレーション総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオシミュレーション市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• ソフトウェア
• サービス
• 世界のバイオシミュレーション市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品開発
• 創薬
• その他の用途
• 世界のバイオシミュレーション市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬・バイオテクノロジー企業
• 医薬品開発業務受託（CRO）
• 規制当局
• 学術研究機関
• その他のエンドユーザー
• 世界のバイオシミュレーション市場：ソフトウェアのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬物動態（PK）シミュレーションソフトウェア
• 薬力学（PD）シミュレーションソフトウェア
• 毒性学シミュレーションソフトウェア
• 疾患モデリングソフトウェア
• 統合バイオシミュレーションプラットフォーム
• 世界のバイオシミュレーション市場：サービスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コンサルティングサービス
• モデル開発サービス
• データ分析および解釈サービス
• トレーニングおよびサポートサービス
• カスタムシミュレーションサービス

第7章 地域別・国別分析

• 世界のバイオシミュレーション市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のバイオシミュレーション市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミュレーション市場：競合情勢
• バイオシミュレーション市場：企業プロファイル
  • Certara Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Dassault Systemes SE Overview, Products and Services, Strategy and Financial Analysis
  • Schrodinger Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Simulations Plus Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Rhenovia Pharma SAS Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Insilico Biotechnology AG
• Genedata AG
• Entelos Inc.
• Physiomics plc
• Rosa & Co. LLC.
• In Silico Biosciences Inc.
• INOSIM Software GmbH
• LeadInvent Technologies Limited
• Nuventra Pharma Sciences Inc.
• Archimedes Inc.
• VeriSIM Life Inc.
• Compugen Inc.
• Leadscope Inc.
• Pharmaceutical Product Development LLC
• Advanced Chemistry Development Inc.

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオシミュレーション市場2029年-最も新しい機会を提供する国
• バイオシミュレーション市場2029年-最も新しい機会を提供するセグメント
• バイオシミュレーション市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.

The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.

The biosimulation market research report is one of a series of new reports from The Business Research Company that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biosimulation market size has grown rapidly in recent years. It will grow from $4.47 billion in 2024 to $5.02 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growing complexity of diseases, rise of in silico trials, drug development cost reduction, growing complexity of diseases, rising prevalence of chronic diseases.

The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $9.65 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to biosimulation in rare disease research, focus on pharmacodynamics modeling, patient stratification in clinical trials, rapid growth in biopharmaceuticals, biosimulation for drug repurposing, demand for safer and more efficacious drugs. Major trends in the forecast period include digital r&d strategies, technological advancements in simulation software, biosimulation for biomarker identification, optimization of clinical trial design, digital biomarkers and endpoints, continuous advancements in computational biology.

The rise in global healthcare expenditure is expected to bolster the biosimulation market during the forecast period. Increased healthcare spending is anticipated to lead to higher investments in drug development, thereby boosting the revenue generated from biosimulation solutions. Biosimulation software is increasingly being utilized in drug development to simulate diseases. This technology enables virtual clinical trials for new pharmaceutical drugs by using computers to run disease simulations. For example, in July 2024, the American Medical Association, a US-based organization, reported that U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person. Therefore, the surge in healthcare expenditure is driving the growth of the biosimulation market.

The rising prevalence of chronic diseases is expected to propel the growth of the biosimulation market going forward. Chronic diseases are medical conditions that persist over an extended period of time, often for a person's lifetime. Biosimulation plays a crucial role in understanding the complex mechanisms underlying chronic diseases, aiding in drug development and personalized treatment strategies. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million fatalities, constituting 74% of the total deaths attributed to non-communicable diseases (NCDs) or chronic conditions worldwide each year. These fatalities encompassed 17. 9 million deaths due to cardiovascular diseases, 9. 3 million deaths related to cancer, 4. 1 million deaths associated with chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the growth of the biosimulation market.

Product innovation is becoming a key trend in the biosimulation market, with several companies focusing on developing new and advanced solutions. For example, in June 2023, Certara, Inc., a Pennsylvania-based company that accelerates drug development using proprietary biosimulation software, technology, and services, launched its new Phoenix Biosimulation Software. This software enhances pharmacokinetic (PK) and pharmacodynamic (PD) modeling, improving the efficiency of drug development while reducing costs. It achieves this through streamlined workflows and integrated data analysis tools, offering a more efficient approach to traditional drug discovery and development.

Major companies operating in the biosimulation market are focusing on cloud-based biosimulation to gain a competitive edge in the market. Cloud-based biosimulation software enables researchers to model and analyze complex biological processes remotely, facilitating collaboration and scalability in life sciences. For instance, in October 2023, Optibrium, a UK-based developer of software solutions for small molecule design, optimization, and data analysis, launched a cloud-based version of its drug discovery platform, StarDrop. The updated version maintains the full range of features and user engagement found in the desktop application. Additionally, it enhances accessibility and reduces the overall cost of ownership for clients. StarDrop, now cloud-based, is accessible from any internet-connected device, offering users a flexible way to utilize the software.

In September 2022, Cadence Design Systems Inc., a US-based computer software company acquired OpenEye Scientific Software for an undisclosed amount. With this acquisition Cadence Design Systems, Inc. is focusing on enhancing its capabilities in the field of computational molecular modeling and simulation, particularly within the realm of drug discovery and design. OpenEye Scientific Software is a US-based software company providing bio simulations software tools.

Major companies operating in the biosimulation market include Certara Inc., Dassault Systemes SE, Schrodinger Inc., Simulations Plus Inc., Rhenovia Pharma SAS, Insilico Biotechnology AG, Genedata AG, Entelos Inc., Physiomics plc, Rosa & Co. LLC., In Silico Biosciences Inc., INOSIM Software GmbH, LeadInvent Technologies Limited, Nuventra Pharma Sciences Inc., Archimedes Inc., VeriSIM Life Inc., Compugen Inc., Leadscope Inc., Pharmaceutical Product Development LLC, Advanced Chemistry Development Inc., Chemical Computing Group Inc., Immunetrics and PPD Inc., Instem India Private Limited, Evidera Inc., Biomodels LLC, PhysioStim SA, Lhasa Limited, SimBioSys Inc., Cadence Design Systems Inc., Allucent Inc.

North America was the largest region in the biosimulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimulation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimulation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Software; Services
• 2) By Application: Drug Development; Drug Discovery; Other Applications
• 3) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations (CROs); Regulatory Authorities; Academic Research Institutions; Other End Users
• Subsegments:
• 1) By Software: Pharmacokinetics (PK) Simulation Software; Pharmacodynamics (PD) Simulation Software; Toxicology Simulation Software; Disease Modeling Software; Integrated Biosimulation Platforms
• 2) By Services: Consulting Services; Model Development Services; Data Analysis And Interpretation Services; Training And Support Services; Custom Simulation Services.
• Companies Mentioned: Certara Inc.; Dassault Systemes SE; Schrodinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimulation Market Characteristics

3. Biosimulation Market Trends And Strategies

4. Biosimulation Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biosimulation Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biosimulation PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biosimulation Market Growth Rate Analysis
• 5.4. Global Biosimulation Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biosimulation Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biosimulation Total Addressable Market (TAM)

6. Biosimulation Market Segmentation

• 6.1. Global Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Software
• Services
• 6.2. Global Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Development
• Drug Discovery
• Other Applications
• 6.3. Global Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Regulatory Authorities
• Academic Research Institutions
• Other End Users
• 6.4. Global Biosimulation Market, Sub-Segmentation Of By Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacokinetics (PK) Simulation Software
• Pharmacodynamics (PD) Simulation Software
• Toxicology Simulation Software
• Disease Modeling Software
• Integrated Biosimulation Platforms
• 6.5. Global Biosimulation Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consulting Services
• Model Development Services
• Data Analysis and Interpretation Services
• Training and Support Services
• Custom Simulation Services

7. Biosimulation Market Regional And Country Analysis

• 7.1. Global Biosimulation Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biosimulation Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimulation Market

• 8.1. Asia-Pacific Biosimulation Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimulation Market

• 9.1. China Biosimulation Market Overview
• 9.2. China Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimulation Market

• 10.1. India Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimulation Market

• 11.1. Japan Biosimulation Market Overview
• 11.2. Japan Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimulation Market

• 12.1. Australia Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimulation Market

• 13.1. Indonesia Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimulation Market

• 14.1. South Korea Biosimulation Market Overview
• 14.2. South Korea Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimulation Market

• 15.1. Western Europe Biosimulation Market Overview
• 15.2. Western Europe Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimulation Market

• 16.1. UK Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimulation Market

• 17.1. Germany Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimulation Market

• 18.1. France Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimulation Market

• 19.1. Italy Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimulation Market

• 20.1. Spain Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimulation Market

• 21.1. Eastern Europe Biosimulation Market Overview
• 21.2. Eastern Europe Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimulation Market

• 22.1. Russia Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimulation Market

• 23.1. North America Biosimulation Market Overview
• 23.2. North America Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimulation Market

• 24.1. USA Biosimulation Market Overview
• 24.2. USA Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimulation Market

• 25.1. Canada Biosimulation Market Overview
• 25.2. Canada Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimulation Market

• 26.1. South America Biosimulation Market Overview
• 26.2. South America Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimulation Market

• 27.1. Brazil Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimulation Market

• 28.1. Middle East Biosimulation Market Overview
• 28.2. Middle East Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimulation Market

• 29.1. Africa Biosimulation Market Overview
• 29.2. Africa Biosimulation Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biosimulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biosimulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimulation Market Competitive Landscape And Company Profiles

• 30.1. Biosimulation Market Competitive Landscape
• 30.2. Biosimulation Market Company Profiles
  • 30.2.1. Certara Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Dassault Systemes SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Schrodinger Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Simulations Plus Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Rhenovia Pharma SAS Overview, Products and Services, Strategy and Financial Analysis

31. Biosimulation Market Other Major And Innovative Companies

• 31.1. Insilico Biotechnology AG
• 31.2. Genedata AG
• 31.3. Entelos Inc.
• 31.4. Physiomics plc
• 31.5. Rosa & Co. LLC.
• 31.6. In Silico Biosciences Inc.
• 31.7. INOSIM Software GmbH
• 31.8. LeadInvent Technologies Limited
• 31.9. Nuventra Pharma Sciences Inc.
• 31.10. Archimedes Inc.
• 31.11. VeriSIM Life Inc.
• 31.12. Compugen Inc.
• 31.13. Leadscope Inc.
• 31.14. Pharmaceutical Product Development LLC
• 31.15. Advanced Chemistry Development Inc.

32. Global Biosimulation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimulation Market

34. Recent Developments In The Biosimulation Market

35. Biosimulation Market High Potential Countries, Segments and Strategies

• 35.1 Biosimulation Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biosimulation Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biosimulation Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer